Heron Therapeutics CFO Ira Duarte Receives 3,874 Shares; 1,101 Withheld

What Happened

• Ira Duarte, Chief Financial Officer of Heron Therapeutics (HRTX), had 3,874 restricted stock units convert to common shares on 2026-07-19. Of those, 1,101 shares were withheld to cover tax obligations (disposition), valued at $0.47/share for a total tax withholding of $517. Net shares delivered to Duarte: 2,773.
• The conversion/derivative entry shows $0.00 exercise price (this reflects RSU conversion rather than a paid option exercise). This was not an open-market sale—it is vesting/conversion and tax withholding.

Key Details

• Transaction date: 2026-07-19; Form 4 filed 2026-07-20 (timely).
• Transactions reported: M = exercise/conversion of derivative (3,874 shares acquired/converted); F = tax withholding (1,101 shares disposed at $0.47 for $517).
• Net new shares issued to insider: 2,773 (3,874 acquired – 1,101 withheld).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnotes: F1 = each restricted stock unit (RSU) converts to one share; F2 = the RSUs vest in 16 equal quarterly installments beginning 01/19/2024.
• No 10b5-1 plan or sale in market reported in this filing.

Context

• This is a routine RSU conversion and tax-withholding event (common when RSUs vest). Tax withholding (code F) is not a market sale signal; it simply satisfies tax obligations.
• Because there was no open-market sale or purchase reported, this filing should be read as issuance/vesting activity rather than an insider expressing a buy/sell sentiment.